Prof. Niels Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), commented: “We are excited about the upcoming near-term milestones with our key programs, including the interim analysis for the Phase 3 trial with vilobelimab in pyoderma gangrenosum and topline Phase 2a data with INF904. These catalysts could significantly de-risk the Company’s pipeline and unlock significant value, propelling InflaRx closer to our goal of bringing meaningful new therapeutic options to patients suffering from chronic inflammatory conditions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- Cantor starts InflaRx at Overweight ahead of upcoming Phase 3 data
- InflaRx initiated with an Overweight at Cantor Fitzgerald
- InflaRx Approves Key Resolutions at Annual Shareholder Meeting
- InflaRx N.V. Announces 2025 Annual General Meeting Agenda
- InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating